 Harpoon Therapeutics NASDAQ:HARP was downgraded by BidaskClub from a hold rating to a sell rating in a research note issued to investors on Tuesday, BidAskClub reports. HARP has been the subject of a number of other research reports. HC Wainwright reissued a buy rating and issued a 28.00 target price on shares of Harpoon Therapeutics ... 